![]() |
Immobilized Anti-CD19 Antibody Human IgG1 (Inebilizumab) at 2 μg/mL (100 μL/well) can bind Recombinant Human CD19 Protein (Fc & AVI Tag), Biotinylated (Cat: 11880-H41H-B), the EC50 is 15-45 ng/mL(QC tested). |
Immobilized Recombinant Human CD19 Protein (hFc & AVI Tag), Biotinylated, HPLC-verified (Cat: 11880-H41H-B) at 1 μg/mL (100 μl/well) on streptavidin precoated (5 μg/mL, 100 μL/well) can bind Inebilizumab derived Anti-CD19 Antibody , Human IgG1, the EC50 is 4.6-13.8 ng/mL (Routinely tested). |
Cancer Drug Targets
Zola H, et al. (2007) CD molecules 2006-human cell differentiation molecules. J Immunol Methods. 318 (1-2): 1-5.
Ho IC, et al. (2009) GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol. 9 (2): 125-35.
Matesanz-Isabel J, et al. (2011) New B-cell CD molecules. Immunology Letters.134 (2): 104-12.
Carter RH, et al. (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 256 (5053): 105-7.
400-829-0116